Partnering opportunities - Core Therapeutic Areas
We are looking for high-value, truly differentiating first or best-in-class treatments in:
Focus on areas of high unmet need, build on strong mid/late-stage pipeline
Atherosclerosis
- Novel approaches to address unmet needs in Cardiovascular Risk Reduction (CVRR)
Cardiovascular
- Heart Failure
- Next-generation approaches addressing atrial fibrillation, cardiomyopathies, thrombosis and hypertension
- Innovative cardiomyocyte-targeted siRNA delivery
Metabolic
- Novel mechanisms to enable sustained metabolic health
Nephrology
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Chronic Kidney Disease (Stage 3b/4)
- Glomerular diseases, e.g. Alport Syndrome
Avi Spier
Focused on high unmet need autoimmune diseases
Dermatology & Allergy
- Atopic Dermatitis
- Chronic Spontaneous Urticaria (CSU)
- Hidradenitis Suppurativa (HS)
- Lichen Planus
- Vitiligo
- Food allergy
Inflammatory Bowel Disease
- Crohn’s Disease
- Ulcerative Colitis
Rheumatology
- Lupus Nephritis
- Sjögren’s disease
- Spondyloarthropathies
- Systemic Lupus Erythematosus (SLE)
Exploratory Areas
- B cell reset
- Refractory Rheumatoid Arthritis
- Tolerance induction
Dominic Ehrismann
Focus on multiple sclerosis, neurodegenerative, and neuromuscular diseases
Multiple Sclerosis & Immuno-Neurology
- Multiple Sclerosis (MS)
- Other neuroimmunology diseases (e.g., CIDP & MG)
Neurodegeneration
- Amyotrophic lateral sclerosis (ALS)
- Parkinson's Disease (PD)
- Alzheimer's Disease
- Huntington's Disease
- CNS delivery technologies
Neuromuscular
- Myotonic Dystrophy Type 1 (DM1)
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Spinal Muscular Atrophy (SMA)
- Duchenne Muscular Dystrophy (DMD)
- Charcot-Marie-Tooth (CMT)Larger neuromuscular indications
- Muscle delivery technologies
Christopher Adams
Deliver next generation of transformative medicines in priority disease areas
Solid Tumors
- Breast cancers
- Prostate cancers
- Lung cancers
- Pancreatic and Colorectal Cancers
Hematology
- Myeloid malignancies: CML, MPN, AML/MDS
- Lymphoid malignancies: NHL
- Non-malignant heme: PNH, ITP, wAIHA
Radioligand Therapy & Imaging
- Radioligand Therapy (RLT) in solid tumor indications, including novel isotopes, chelators, vectors and targets
- Radioligand Imaging (RLI) or PET imaging agents
